Fate Therapeutics Names Kamal Adawi Chief Financial Officer

Dow Jones

2025/10/14

By Colin Kellaher

Fate Therapeutics has hired Kamal Adawi as the clinical-stage biopharmaceutical company's new chief financial officer, effective Oct. 20.

Fate on Tuesday said Adawi most recently served as finance chief of precision-medicine company Mindera Health.

Bahram Valamehr has been serving as president, chief executive and principal financial officer of Fate since the start of the year following the retirement of J. Scott Wolchko as the San Diego company's president, CEO and chief financial officer.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 14, 2025 08:26 ET (12:26 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575290062"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575290062\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575290062?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 20:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575290062","market":"sh","top_or_hot":-1,"title":"Fate Therapeutics Names Kamal Adawi Chief Financial Officer","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Fate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has hired Kamal Adawi as the clinical-stage biopharmaceutical company's new chief financial officer, effective Oct. 20. \n</p>\n<p>\n  Fate on Tuesday said Adawi most recently served as finance chief of precision-medicine company Mindera Health. \n</p>\n<p>\n  Bahram Valamehr has been serving as president, chief executive and principal financial officer of Fate since the start of the year following the retirement of J. Scott Wolchko as the San Diego company's president, CEO and chief financial officer. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 14, 2025 08:26 ET (12:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fate Therapeutics Names Kamal Adawi Chief Financial Officer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFate Therapeutics Names Kamal Adawi Chief Financial Officer\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-14 20:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Fate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has hired Kamal Adawi as the clinical-stage biopharmaceutical company's new chief financial officer, effective Oct. 20. \n</p>\n<p>\n  Fate on Tuesday said Adawi most recently served as finance chief of precision-medicine company Mindera Health. \n</p>\n<p>\n  Bahram Valamehr has been serving as president, chief executive and principal financial officer of Fate since the start of the year following the retirement of J. Scott Wolchko as the San Diego company's president, CEO and chief financial officer. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 14, 2025 08:26 ET (12:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FATE","symbol_name":"Fate Therapeutics Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2575290062","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575290062","pubTimestamp":1760444760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Fate Therapeutics has hired Kamal Adawi as the clinical-stage biopharmaceutical company's new chief financial officer, effective Oct. 20.Fate on Tuesday said Adawi most recently served as finance chief of precision-medicine company Mindera Health.Bahram Valamehr has been serving as president, chief executive and principal financial officer of Fate since the start of the year following the retirement of J. Scott Wolchko as the San Diego company's president, CEO and chief financial officer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FATE":"Fate Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Fate Therapeutics任命Kamal Adawi为首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FATE":1.5},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Fate Therapeutics has hired Kamal Adawi as the clinical-stage biopharmaceutical company's new chief financial officer, effective Oct. 20. \n\n\n  Fate on Tuesday said Adawi most recently served as finance chief of precision-medicine company Mindera Health. \n\n\n  Bahram Valamehr has been serving as president, chief executive and principal financial officer of Fate since the start of the year following the retirement of J. Scott Wolchko as the San Diego company's president, CEO and chief financial officer. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 14, 2025 08:26 ET (12:26 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}